Evaluation of the safety and effectiveness of switching from standard to extended interval dosing for durvalumab in unresectable stage III non-small cell lung cancer.
2021
e20501Background: In 2018, the FDA approved durvalumab with weight-based dosing of 10 mg/kg every 2 weeks for unresectable, Stage III non-small cell lung cancer (NSCLC) following chemoradiation the...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI